|
14 Companies |
|
12 Products |
|
12 Products |
|
42 Mechanisms of Action |
|
0 Trials |
|
22 News |
|
- | saracatinib (AZD0530) / AstraZeneca
Enrollment change: AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 3, 2018
P2, N=17, Completed, Sponsor: National Cancer Institute (NCI)
N=37 --> 17
- | trebananib (AMG 386) / Amgen
Trial completion, Enrollment change, Trial primary completion date: Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer (clinicaltrials.gov) - May 4, 2017
P2, N=35, Completed, Sponsor: Gynecologic Oncology Group
N=37 --> 17 Active, not recruiting --> Completed | N=55 --> 35 | Trial primary completion date: Mar 2016 --> Jul 2016
- Trial completion: Collecting Tumor Samples From Patients With Gynecological Tumors (clinicaltrials.gov) - Oct 28, 2016
P=N/A, N=275, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed | N=55 --> 35 | Trial primary completion date: Mar 2016 --> Jul 2016 Recruiting --> Completed
- |||| selurampanel (BGG492) / Novartis
Trial completion, Enrollment change, Trial primary completion date: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 (clinicaltrials.gov) - Oct 7, 2015
P2, N=59, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed | N=77 --> 59 | Trial primary completion date: Jun 2015 --> Sep 2015
- |||| selurampanel (BGG492) / Novartis
Enrollment open, Trial primary completion date: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 (clinicaltrials.gov) - Jan 8, 2015
P2, N=77, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=77 --> 59 | Trial primary completion date: Jun 2015 --> Sep 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Jun 2015
- | Granocyte (lenograstim) / Roche
Trial completion, Surgery: EORTC-STBSG 62931: Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 8, 2014
P3, N=350, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Jun 2015 Active, not recruiting --> Completed
- trebananib (AMG 386) / Amgen
Enrollment closed: Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer (clinicaltrials.gov) - Aug 7, 2014
P2, N=55, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- ||||| selurampanel (BGG492) / Novartis
New P2 trial: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 (clinicaltrials.gov) - May 27, 2014
P2, N=77, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | thalidomide / Generic mfg.
Trial completion: Thalidomide in Treating Patients With Gynecologic Sarcomas (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: New York University Cancer Institute
Suspended --> Active, not recruiting No longer recruiting --> Completed
- | pegylated liposomal doxorubicin / Generic mfg.
Trial completion, Metastases: Chemotherapy in Treating Patients With Sarcoma of the Uterus (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Gynecologic Oncology Group
No longer recruiting --> Completed No longer recruiting --> Completed
- Trial termination: Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer (clinicaltrials.gov) - Jan 30, 2014
P3, N=22, Terminated, Sponsor: University of South Florida
No longer recruiting --> Completed Active, not recruiting --> Terminated; The study was terminated due to slow accrual.
- Enrollment change: Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer (clinicaltrials.gov) - Jan 30, 2014
P3, N=22, Terminated, Sponsor: University of South Florida
Active, not recruiting --> Terminated; The study was terminated due to slow accrual. N=178 --> 22
- BI2536 / Boehringer Ingelheim
Trial completion, Metastases: BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 3, 2013
P2, N=76, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=178 --> 22 Active, not recruiting --> Completed
- BI2536 / Boehringer Ingelheim
Enrollment change, Metastases: BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - Sep 19, 2013
P2, N=76, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed N=185 --> 76
- trebananib (AMG 386) / Amgen
Trial suspension: Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer (clinicaltrials.gov) - May 27, 2013
P2, N=55, Suspended, Sponsor: Gynecologic Oncology Group
N=185 --> 76 Recruiting --> Suspended
- saracatinib (AZD0530) / AstraZeneca
Trial completion: AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - May 6, 2013
P2, N=37, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Active, not recruiting --> Completed
- sunitinib / Generic mfg.
Enrollment change, Metastases: Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas (clinicaltrials.gov) - Mar 19, 2013
P2, N=52, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed N=102 --> 52
- Yondelis (trabectedin) / PharmaMar, J&J
Enrollment change, Metastases: Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=132, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=102 --> 52 N=44 --> 132
- imatinib / Generic mfg.
Trial completion, Metastases: STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=91, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=44 --> 132 Active, not recruiting --> Completed
- Yondelis (trabectedin) / PharmaMar, J&J
Trial completion, Metastases: Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=132, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Surgery: Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus (clinicaltrials.gov) - Sep 19, 2012
P3, N=224, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: SWOG-EORTC-62933: Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 9, 2012
P3, N=340, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed